Pareto reiterates Hold and lowers the target price to SEK 1.7, from 3.0 previously, for the medical technology company Synthetic MR.The analysis firm notes a weak Q3 report with sales down 7 percent year-on-year and EBIT clearly below expectations, although the adjusted earnings were only marginally weaker.Pareto has revised its forecasts down and now expects 15 percent sales growth in 2026, but assesses that the company will likely need to raise around SEK 40 million during 2026 given the cash flow development.The view is that the company is making progress but at a slow pace, and that visibility for a clearer acceleration is still limited.